How to manage patients on long-acting injectable (LAI, or depot) antipsychotics during the COVID-19 pandemic, NIHR
This guidance includes information about LAI antipsychotic medications which are currently licensed in the UK (that is: Xeplion ® , Trevicta ® , Abilify Maintena ® , Risperdal Consta ® , Zypadhera ® ) (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 1, 2020 Category: Consumer Health News Source Type: news

Class 4 Medicines Defect Information: Aripiprazole 1mg/ml Oral Solution,
Mylan UK Healthcare Ltd has informed the MHRA that a product complaint ... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - March 12, 2020 Category: Drugs & Pharmacology Source Type: news

How Aripiprazole's Promise for Treating Autism Fell Short
Aripiprazole, marketed as Abilify, is widely thought to be safer than risperidone, the only other drug approved for use in autistic children. A decade's worth of data suggests that is not true. (Source: The Scientist)
Source: The Scientist - February 27, 2020 Category: Science Tags: News & Opinion Source Type: news

Class 2 Medicines Recall: Aripiprazole 1mg/ml oral solution
Dr. Reddy's Laboratories (UK) Ltd is recalling a specified batch of Aripiprazole 1mg/ml oral solution due to the potential for small particles of Aripiprazole active material to be present which m (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - September 12, 2019 Category: Drugs & Pharmacology Source Type: news

Class 2 Medicines Recall: aripiprazole 1mg/ml oral solution
Accord-UK Ltd is recalling certain batches of aripiprazole 1mg/ml oral solution. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - July 30, 2019 Category: Drugs & Pharmacology Source Type: news

Haldol (haloperidol) vs. Abilify (aripiprazole)
Title: Haldol (haloperidol) vs. Abilify (aripiprazole)Category: MedicationsCreated: 7/30/2019 12:00:00 AMLast Editorial Review: 7/30/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 30, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approval of First Digital Pill Based on'Weak Evidence'FDA Approval of First Digital Pill Based on'Weak Evidence '
A review of the data that led to the FDA approval of digital aripiprazole suggests the evidence is weak and raises concerns about technology-enhanced products to'evergreen'drugs going off patent.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - July 24, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news

Long-Acting Injectables Yield Similar Benefit in Schizophrenia Long-Acting Injectables Yield Similar Benefit in Schizophrenia
Aripiprazole lauroxil once every 2 months provided similar significant improvement in schizophrenia symptoms as once per month paliperidone palmitate.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 11, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news

A Pill, That ’s a Device, That Delivers a Drug!
Rani Therapeutics just achieved one of its most significant milestones since it was spun out of InCube Lab in 2012. The San Jose, CA-based company just finished conducting the first human study of its “robotic capsule” set to replace injections. Previously the device, which administers a pharmaceutical through a digestible pill, had been tested in more than 100 animal models. The human study was conducted at a Clinical Research Organization (CRO) in Texas under the Investigational Review Board (IRB) approval. There were two sub-groups, one cohort was fed and another fasted. Each subject ...
Source: MDDI - February 28, 2019 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

Aripiprazole Switch Not Linked With Increased Risk of Psychiatric Treatment Failure (CME/CE)
(MedPage Today) -- No association between use of agent and higher risk of hospitalization, self-harm, and suicide (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - February 5, 2019 Category: Neurology Source Type: news

Aripiprazole Self-harm, Suicide Risk: Is It Real? Aripiprazole Self-harm, Suicide Risk: Is It Real?
Previous research shows that initiation of the antipsychotic may be tied to an increased risk for suicide, self-harm, or psychiatric hospitalization. But a new study suggests there is no such link.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 4, 2019 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Association of aripiprazole with the risk for psychiatric hospitalization, self-harm, or suicide - Montastruc F, Nie R, Loo S, Rej S, Dell'Aniello S, Micallef J, Suissa S, Renoux C.
IMPORTANCE: Some reports have raised concerns regarding a potential psychiatric worsening associated with first-time use of aripiprazole in patients already treated with other antipsychotic medications. Whether aripiprazole use, particularly in the long te... (Source: SafetyLit)
Source: SafetyLit - February 1, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

No Suicide Bump When Adding, Switching to Aripiprazole
(MedPage Today) -- But its effect on milder psychiatric exacerbations needs further examination (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - January 31, 2019 Category: Psychiatry Source Type: news

Abilify MyCite (Aripiprazole Tablets with Sensor) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 6, 2018 Category: Drugs & Pharmacology Source Type: news

Proteus, Otsuka expand their digital medicine collaboration with five-year, $88M deal
As the Abilify MyCite platform nears a full rollout, the companies said they are looking forward to employing the technology toward additional mental health therapies. (Source: mobihealthnews)
Source: mobihealthnews - October 15, 2018 Category: Information Technology Source Type: news

Otsuka, Magellan Health announce plans for US rollout of Abilify MyCite
The two companies are planning a limited initial deployment to gather additional real-world data before a wider release. (Source: mobihealthnews)
Source: mobihealthnews - August 30, 2018 Category: Information Technology Source Type: news

The Line Between Drugs and Devices Continues to Blur
Otsuka America Pharmaceutical has signed a collaboration agreement with Magellan Health designed to facilitate access to the first drug-device combination product approved by FDA to track drug ingestion. The agreement creates an opportunity for doctors and adult patients to gather experience in a real-world setting with the Abilify Mycite System, Princeton, NJ-based Otsuka said on Thursday. The Abilify Mycite System is the perfect example of how the line between pharma and medtech continues to blur, which isn't necessarily a bad thing. The product is comprised of Otsuka's oral aripiprazole tablets embedded with...
Source: MDDI - August 30, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Source Type: news

Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US
Otsuka Pharmaceutical (TYO:4578) said today it inked a collaborative deal with health management group Magellan Health to distribute its drug-device combo Abilify Mycite in the US. The Tokyo-based pharmaceutical company touted the Abilify Mycite system as the first FDA-approved drug-device combo designed to track drug ingestion, and said that the tracking data will be integrated into Magellan Health’s mental health provider network. Read the whole story on our sister site, Drug Delivery Business News The post Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution Drug-Device Combinations Neurological Otsuka Holdings Source Type: news

Aristada Initio (Aripiprazole Lauroxil Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 24, 2018 Category: Drugs & Pharmacology Source Type: news

Aristada Initio (Aripiprazole Lauroxil Injectable Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 19, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves Aristada Initio (aripiprazole lauroxil) for the Initiation of Aristada for Schizophrenia
DUBLIN, July 2, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Aristada Initio (aripiprazole lauroxil) for the initiation of Aristada (aripiprazole lauroxil), a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 2, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Clears'Day One' Aristada Regimen for Treating Schizophrenia FDA Clears'Day One' Aristada Regimen for Treating Schizophrenia
The FDA has cleared an extended-release injectable version of aripiprazole lauroxil, making it the'first and only long-acting atypical antipsychotic that can be initiated on day one,'say researchers.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 2, 2018 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA OK's 1-Day Initiation for Long-Acting Injectable Schizophrenia Tx
(MedPage Today) -- May replace previous 21-day initiation regimen onto aripiprazole lauroxil (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 2, 2018 Category: American Health Source Type: news

Aripiprazole-induced Sleep-related Eating Disorder Aripiprazole-induced Sleep-related Eating Disorder
This case of sleep-related eating disorder in a patient taking aripiprazole for depression suggests that this disorder should be considered as a potential side effect of this drug.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2018 Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news

Aripiprazole Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - June 5, 2018 Category: Drugs & Pharmacology Source Type: news

Antipsychotic May Fuel Urge to Gamble Antipsychotic May Fuel Urge to Gamble
An updated literature review provides more evidence of an association between gambling disorder and the second-generation atypical antipsychotic aripiprazole.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

One-Day Injectable Aripiprazole Tx Passes Test
(MedPage Today) -- Results comparable to traditional 21-day oral regimen (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 8, 2018 Category: Primary Care Source Type: news

The Drugs That Changed Our Minds by Lauren Slater – review
Twenty years after hailing antidepressants in her memoir Prozac Diary, a now jaded, sceptical Lauren Slater revisits the psychopharmacological industry – with uneven resultsInProzac Diary (1998), Lauren Slater wrote powerfully of the way fluoxetine had transformed her previously chaotic life. While the author recorded a handful of negative side-effects – a profound loss of libido, for instance – the reader was left with the sense that Prozac had pieced back together the shards of Slater’s existence. In some ways,The Drugs That Changed Our Minds is a sequel to that book. Slater is now in her mid-50s,...
Source: Guardian Unlimited Science - April 1, 2018 Category: Science Authors: Alex Preston Tags: Autobiography and memoir Science and nature Books Medical research Depression Society Culture Source Type: news

Proteus CMO talks regulation hurdles, future plans for digital pill
It ’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare. (Source: mobihealthnews)
Source: mobihealthnews - March 8, 2018 Category: Information Technology Source Type: news

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation) - Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB.
BACKGROUND: People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations. OBJECTIVES: To evaluate the effects of intramuscular aripiprazole in the treatment of psych... (Source: SafetyLit)
Source: SafetyLit - January 15, 2018 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news

Pharma news in clinical trials, chronic condition management, and innovation from Q4 2017
Digital health in pharma definitely had a milestone moment in the fourth quarter with the FDA approval of Abilify MyCite, a new, sensor-enabled version of Otsuka ’s drug for schizophrenia powered by Proteus Digital Health’s ingestible sensor technology. In addition to that, the quarter saw numerous other moves by pharma companies around clinical trials, chronic disease management, mental health, and, more generally, innovation. (Source: mobihealthnews)
Source: mobihealthnews - December 27, 2017 Category: Information Technology Source Type: news

Gene Polymorphisms and Aripiprazole-induced Autonomic Dysfunction Gene Polymorphisms and Aripiprazole-induced Autonomic Dysfunction
Certain polymorphisms in the ABCB1 gene appear to be linked to aripiprazole-induced autonomic nervous system dysfunction in patients with schizophrenia, researchers from Japan report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 20, 2017 Category: Pathology Tags: Psychiatry News Source Type: news

New FDA-approved "trackable" pill transmits information it will tattle on you if you don't take your meds
(Natural News) The U.S. Food and Drug Administration (FDA) recently approved a digital pill embedded with a sensor designed to inform physicians whether their patients are taking their medications. The federal approval marks a growing trend towards addressing drug non-adherence among patients, according to a New York Times report. The pill, called Abilify MyCite, is a modified version... (Source: NaturalNews.com)
Source: NaturalNews.com - December 13, 2017 Category: Consumer Health News Source Type: news

Abilify MyCite (Aripiprazole Tablets with Sensor) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 27, 2017 Category: Drugs & Pharmacology Source Type: news

In-Depth: How digital sensors could change the face of pharma
Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka ’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and bipolar disorder. (Source: mobihealthnews)
Source: mobihealthnews - November 17, 2017 Category: Information Technology Source Type: news

FDA Approves First Pill with Digital Tracker
The FDA has approved a new version of the antipsychotic aripiprazole embedded with a digital sensor to allow patients to track when the medication was... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 15, 2017 Category: Primary Care Source Type: news

Digital pill could address a "big problem" with medication
CBS News chief medical correspondent Dr. Jon LaPook explains how the digital pill, Abilify MyCite, works (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2017 Category: Consumer Health News Source Type: news

Otsuka, Proteus finally win FDA approval for sensor-equipped Abilify
The first drug in the US with a digital ingestion tracking system has been approved by the FDA. The pill, Abilify MyCite, is prescribed for treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and as an add-on treatment for depression in adults. (Source: mobihealthnews)
Source: mobihealthnews - November 14, 2017 Category: Information Technology Source Type: news

FDA approves first trackable pill that syncs with a phone
The FDA approved a pill that tracks when patients take their prescribed psychiatric drug. The medication, Abilify MyCite, is a variation on a drug used to treat schizophrenia and bipolar disorder. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA Clears Drug With Ingestible Digital Tracker FDA Clears Drug With Ingestible Digital Tracker
Abilify MyCite is the first drug approved in the United States that has a digital tracking system for patients and providers to monitor medication intake.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

'Digital Pill' Lets Doctors Know It's Been Taken
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. (Source: WebMD Health)
Source: WebMD Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA OKs First 'Digital Pill' That Lets Doctors Know It's Been Taken
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. (Source: WebMD Health)
Source: WebMD Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA approves first pill with sensor to track ingestion
The FDA today approved Abilify MyCite, the first drug in the U.S. to have an ingestible sensor embedded within the pill that can track if the medication was taken. The drug-device combination product is indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes linked with bipolar I disorder and as an add-on treatment for depression in adults. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves first pill with sensor to track ingestion appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Neurological Patient Monitoring Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news

' Digital Pill', Abilify Mycite, Tells Doctor When Patient Takes It
TUESDAY, Nov. 14, 2017 -- The first drug designed to alert a doctor when a patient takes the medication has been approved by the U.S. Food and Drug Administration. Abilify MyCite (aripiprazole with sensor) has an embedded sensor that sends a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2017 Category: General Medicine Source Type: news

FDA OKs First'Digital Pill', Abilify Mycite, That Lets Doctors Know It's Been Taken
TUESDAY, Nov. 14, 2017 -- Offering both the promise of better patient compliance with health care, but also fears of a medical " Big Brother, " a newly approved " digital pill " allows physicians to track whether or not it's been ingested by... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2017 Category: General Medicine Source Type: news

FDA approves first drug in U.S. with digital ingestion tracking
(Reuters) - The U.S. Food and Drug Administration said on Monday that it had approved Otsuka Pharmaceutical Co Ltd's Abilify MyCite, the first drug with a digital ingestion tracking system to be approved in the United States. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves pill with sensor that digitally tracks if patients have ingested their medication
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 14, 2017 Category: American Health Source Type: news

FDA Approves Pill with Sensor that Digitally Tracks if Patients Have Ingested their Medication
The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: eHealth News EU)
Source: eHealth News EU - November 14, 2017 Category: Information Technology Tags: Featured Development Research and Development Source Type: news